Denis Roy

The Caisse de dépôt et placement du Québec (CDPQ) is a government-owned institutional fund manager headquartered in Montréal, Canada. Founded in 1965, CDPQ manages the funds of several depositor groups primarily for public and parapublic pension and insurance plans which pay out benefits to more than two million Quebecers each year.

Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA.

BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.

Mechtronix Systems Inc. manufactures equipment and devices for commercial aviation. The firm provides airlines training, multicrew pilot license, pilot provisioning, full flight simulator and ascent series for general aviation. The company was founded by Xavier-Henri Hervé, Fernando Petruzziello, Joaquim Frazao, Marco Petruzziello and Thomas Allen in 1987 and is headquartered at Saint-Laurent, Canada.

CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

Bellus Health (Innodia), Inc. manufactures biopharmaceutical products for the treatment and prevention of amyloidosis, metabolic syndrome, and diabetics related diseases. The company was founded in 2002 and is headquartered in Laval, Canada.

GeneChem Management Inc (GeneChem) is an independent venture capital firm founded in 1997. The firm is headquartered in Montréal.

Réseau Capital operates as a venture capital and private equity association. It promotes private equity industry in Quebec through training, information and promotion, networking, and representation. The company was founded by Jean-Pierre Chartrand in 1989 and is headquartered in Montréal, Canada.

AgeChem Financial, Inc. engages in the provision of investment services, It seeks to invest in companies developing therapeutics targeting age-related diseases. The company was founded in 2006 and is headquartered in Montreal, Canada.

Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada.

2154331 Canada, Inc. designs and manufactures flight training equipment. The firm offers products to airlines, training centers and training organizations such as CAFUC, Center Air, Copa Airlines, IFTC Istanbul, JAL training center, and Japan Airlines. The company was founded by Fernando Petruzziello and Joaquim Frazao in 1987 and is headquartered in Saint-Laurent, Canada.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Center for Drug Research & Development operates as a drug development and commercialization company. The firm provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector and ultimately into new therapies for patients. The company was founded in 2007 and is headquartered in Vancouver, Canada.

Natunola AgriTech, Inc. develops, manufactures and markets proprietary natural ingredients. It offers ingredients to the personal care, food and nutraceutical markets. The company was founded on June 30, 2004 and is headquartered in Winchester, Canada.

AmorChem Financial, Inc. provides financial investment services. The company is headquartered in Westmount, Canada.

Sitka Biopharma, Inc. develops novel polymer platform technology that improves drug absorption for cancer treatments. The company was founded by Michael Parr in 2013 and is headquartered in Vancouver, the United Kingdom.

ARTMS, Inc. operates as biotechnology company, which develops novel technology and products. The company was founded by Michael Cross and is headquartered in Burnaby, Canada.

Nimbus Synergies Inc (Nimbus Synergies) is a venture capital firm founded in 2017 by Jason Robertson. The firm is headquartered in British Columbia, Canada.

Zucara Therapeutics, Inc. develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people. The company is headquartered in Toronto, Canada.

TRIUMF Innovations, Inc. is the business interface and commercialization arm of TRIUMF, Canada's particle accelerator center. The private company is based in Vancouver, Canada. The Canadian company connects TRIUMF to the private sector through industry partnerships, licensing, and company creation. Kathryn Hayashi has been the CEO of the company since 2017.

Epitopea Ltd. is a British transatlantic biotechnology company that develops immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. The company is based in Cambridge, UK. The company has an extensive proprietary library of cryptigen™ tsas that will drive the development of transformational off the shelf cancer immunotherapies. Epitopea was founded in 2021 by Jonathan David Moore, Claude Perreault, and Pierre Thibault. Jonathan David Moore has been the CEO since 2021.